Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)
Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the outcomes of patients with chronic kidney disease
(CKD) randomly assigned to 2 treatment groups, which differ only in their targeted hemoglobin
levels. This study will test the primary hypothesis that the level of anemia correction with
once weekly dosing of PROCRIT® (Epoetin alfa) in patients with chronic kidney disease will
decrease mortality and cardiovascular morbidity.
Phase:
Phase 4
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.